Plain-English translation of NCT06232083 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a combination of two treatments: a new radiation technique called pulsed low-dose rate external irradiation (PLDR) paired with an immune-boosting medication called cardonizumab. Researchers believe that the radiation may help your immune system work better when combined with this medication, potentially offering hope for people whose cancers have returned or spread after previous treatment.
Current treatments for cancers that come back or spread have limited success rates. This medication shows promise on its own, but doctors want to see if the special radiation therapy can make it work even better by helping your body's immune system fight the cancer more effectively.
You likely qualify if…
You likely don't qualify if…
You would receive radiation therapy five times a week for four weeks while also receiving the immune-boosting medication on a set schedule. After the radiation ends, you would continue the medication at a maintenance dose for up to 2 years. You will have regular blood tests and imaging scans to monitor how you're responding, and researchers will track any side effects throughout your participation.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China